Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
暂无分享,去创建一个
Hartwig Huland | Markus Graefen | Michael W Kattan | Andreas Erbersdobler | M. Kattan | P. Scardino | J. Eastham | M. Graefen | H. Huland | T. Wheeler | S. Shariat | A. Erbersdobler | K. Slawin | Peter T Scardino | James A Eastham | Shahrokh F Shariat | Thomas M Wheeler | Norio Maru | Hideshige Koh | Kevin M Slawin | Makoto Ohori | M. Ohori | Hideshige Koh | N. Maru
[1] P. Walsh,et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. , 2002, The Journal of urology.
[2] T. Wheeler,et al. Heterogeneity of prostate cancer in radical prostatectomy specimens. , 1994, Urology.
[3] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[4] J. Hanley,et al. Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .
[5] Neil Fleshner,et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.
[6] P. Walsh,et al. The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. , 1999, The Journal of urology.
[7] R. Kronmal. Spurious Correlation and the Fallacy of the Ratio Standard Revisited , 1993 .
[8] D. Chan,et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. , 1998, The Journal of urology.
[9] J. Cerhan,et al. Prostate Cancer Trends 1973-1995, SEER Program National Cancer Institute. , 1999 .
[10] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[11] M W Kattan,et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. , 1996, The Journal of urology.
[12] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[13] P. Walsh,et al. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. , 1997, Journal of Urology.
[14] P. Schellhammer,et al. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. , 2001, The Journal of urology.
[15] Peter H Gann,et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.
[16] T. Stamey,et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. , 1994, The Journal of urology.
[17] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[18] J. Epstein,et al. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. , 1997, The American journal of surgical pathology.
[19] T. Stamey,et al. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. , 2001, The Journal of urology.
[20] P. Scardino,et al. Early detection of prostate cancer. , 1989, The Urologic clinics of North America.
[21] Michael W Kattan,et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.